JP2023554492A5 - - Google Patents

Info

Publication number
JP2023554492A5
JP2023554492A5 JP2023537470A JP2023537470A JP2023554492A5 JP 2023554492 A5 JP2023554492 A5 JP 2023554492A5 JP 2023537470 A JP2023537470 A JP 2023537470A JP 2023537470 A JP2023537470 A JP 2023537470A JP 2023554492 A5 JP2023554492 A5 JP 2023554492A5
Authority
JP
Japan
Prior art keywords
formula
compound
approximately
mixture
fumarate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023537470A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023554492A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/061895 external-priority patent/WO2022130304A1/en
Publication of JP2023554492A publication Critical patent/JP2023554492A/ja
Publication of JP2023554492A5 publication Critical patent/JP2023554492A5/ja
Pending legal-status Critical Current

Links

JP2023537470A 2020-12-18 2021-12-17 共結晶のcdk阻害剤 Pending JP2023554492A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202041055174 2020-12-18
IN202041055174 2020-12-18
PCT/IB2021/061895 WO2022130304A1 (en) 2020-12-18 2021-12-17 Cocrystal of a cdk inhibitor

Publications (2)

Publication Number Publication Date
JP2023554492A JP2023554492A (ja) 2023-12-27
JP2023554492A5 true JP2023554492A5 (cg-RX-API-DMAC10.html) 2024-12-25

Family

ID=80001496

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023537470A Pending JP2023554492A (ja) 2020-12-18 2021-12-17 共結晶のcdk阻害剤

Country Status (17)

Country Link
US (1) US20240059669A1 (cg-RX-API-DMAC10.html)
EP (1) EP4263534A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023554492A (cg-RX-API-DMAC10.html)
KR (1) KR20230159363A (cg-RX-API-DMAC10.html)
CN (1) CN116685326A (cg-RX-API-DMAC10.html)
AU (1) AU2021402415A1 (cg-RX-API-DMAC10.html)
CA (1) CA3202198A1 (cg-RX-API-DMAC10.html)
CL (1) CL2023001753A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023009368A2 (cg-RX-API-DMAC10.html)
CR (1) CR20230261A (cg-RX-API-DMAC10.html)
DO (1) DOP2023000126A (cg-RX-API-DMAC10.html)
EC (1) ECSP23054131A (cg-RX-API-DMAC10.html)
IL (1) IL303738A (cg-RX-API-DMAC10.html)
MX (1) MX2023007218A (cg-RX-API-DMAC10.html)
PE (1) PE20231441A1 (cg-RX-API-DMAC10.html)
TW (1) TW202241881A (cg-RX-API-DMAC10.html)
WO (1) WO2022130304A1 (cg-RX-API-DMAC10.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4232010A4 (en) * 2020-10-22 2024-09-04 Aurigene Oncology Limited CANCER THERAPY USING A CDK7 INHIBITOR IN COMBINATION WITH AN ANTI-MICROTUBULE AGENT
TW202329937A (zh) 2021-12-03 2023-08-01 美商英塞特公司 雙環胺ck12抑制劑
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
WO2023224961A1 (en) 2022-05-16 2023-11-23 Exelixis, Inc. Cancer therapy using a combination of a cdk7 inhibitor with an oral serd
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
CN118772106A (zh) * 2024-06-07 2024-10-15 山东大学 伊马替尼-没食子酸共晶、其溶剂化物、制备方法和应用
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3302448T3 (da) * 2015-06-04 2024-02-05 Aurigene Oncology Ltd Erstattede heterocyclylafledninger som cdk-inhibitore

Similar Documents

Publication Publication Date Title
CN107793413B (zh) 嘧啶杂环化合物及其制备方法和应用
JP2019532089A5 (cg-RX-API-DMAC10.html)
KR20230159363A (ko) Cdk 억제제의 공결정
US20250281492A1 (en) New crystalline forms of salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide
JP7257328B2 (ja) ベンゾフラン誘導体遊離塩基の結晶およびその製造方法
JP2024526882A5 (cg-RX-API-DMAC10.html)
KR20100085142A (ko) C-met/hgfr 억제제의 다형체
JP7778750B2 (ja) 3-(5-フルオロベンゾフラン-3-イル)-4-(5-メチル-5H-[1,3]ジオキソロ[4,5-f]インドール-7-イル)ピロール-2,5-ジオンの固体形態
JP2024500101A (ja) 化合物の固体形態
WO2017152707A1 (zh) 吡啶胺基嘧啶衍生物甲磺酸盐的结晶形式及其制备和应用
WO2020057546A1 (zh) 环状二核苷酸类似物、其药物组合物及应用
JP2024518429A5 (cg-RX-API-DMAC10.html)
CN112424187B (zh) 抑制jak的化合物的昔萘酸盐
JP7054528B2 (ja) プロテインキナーゼ活性を抑制する化合物の結晶形態、及びその適用
TW202308991A (zh) 三苯化合物之固體形式
TWI780077B (zh) 噻吩並嘧啶類化合物、其製備方法、藥用組合物及其應用
JP2007277241A (ja) (2R,Z)−2−アミノ−2−シクロヘキシル−N−(5−(1−メチル−1H−ピラゾール−4−イル)−1−オキソ−2,6−ジヒドロ−1H−[1,2]ジアゼピノ[4,5,6−cd]インドール−8−イル)アセトアミドの多形体
TW201817733A (zh) 一種GnRH受體拮抗劑的多晶型及其製備方法
JP7776258B2 (ja) 3-(5-フルオロベンゾフラン-3-イル)-4-(5-メチル-5H-[1,3]ジオキソロ[4,5-f]インドール-7-イル)ピロール-2,5-ジオンの固体形態
CN114805331B (zh) N连接的杂芳环类化合物
WO2019201296A1 (zh) 作为rho激酶抑制剂的吡唑类化合物
JP7618575B2 (ja) N-(5-((4-エチルピペラジン-1-イル)メチル)ピリジン-2-イル)-5-フルオロ-4-(3-イソプロピル-2-メチル-2h-インダゾール-5-イル)ピリミジン-2-アミンおよびその塩の結晶形態および非晶質形態、ならびにその製造方法および治療的使用
JP2023548605A5 (cg-RX-API-DMAC10.html)
JP5856971B2 (ja) 結晶性cdc7阻害剤塩
CA3158942A1 (en) Processes for preparing 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide